

Decreased Circulating CD28-negative T Cells in Patients with Rheumatoid Arthritis Treated with Abatacept Are Correlated with Clinical Response

MIRKO SCARSI, TAMARA ZIGLIOLI, and PAOLO AIRO*

ABSTRACT. Objective. To verify the hypothesis that blockade of CD28 costimulation by treatment with abatacept in patients with rheumatoid arthritis (RA) might induce a reduction in the number of CD28⁻ T cells, as well as other effector T cell populations. We evaluated whether these variations correlate with clinical response.

Methods. Peripheral blood T cell subsets were longitudinally evaluated by flow cytometry through the analysis of CD28, CD45RA, and CCR7 expression in 16 patients with RA who were treated with abatacept.

Results. After 48 weeks of treatment, the proportion and the absolute number of circulating CD8⁺CD28⁻ T cells decreased ($p = 0.008$, $p = 0.055$, respectively, compared with baseline), as well as the proportion of the CD8⁺CD45RA⁺CCR7⁻ cells, thought to represent terminally differentiated effector T cells ($p = 0.03$). Reductions of percentages of circulating CD4⁺CD28⁻ and CD8⁺CD28⁻ T cells, and (CCR7⁻) CD8⁺ total effector T cells were directly correlated with the reduction of Disease Activity Score 28 C-reactive protein ($r = 0.58$, $p = 0.014$; $r = 0.47$, $p = 0.059$; $r = 0.59$, $p = 0.012$, respectively).

Conclusion. After therapy with abatacept, circulating CD28⁻ T cells and other effector populations decrease in patients with RA. This decrease is correlated with clinical response. (First Release March 15 2010; J Rheumatol 2010;37:911–16; doi:10.3899/jrheum.091176)

Key Indexing Terms:

ABATACEPT

RHEUMATOID ARTHRITIS

CD28-NEGATIVE T CELLS

DISEASE ACTIVITY SCORE

T LYMPHOCYTES

The glycoprotein CD28 is the receptor of costimulatory signals delivered by antigen-presenting cells through the CD80/CD86 family during T cell activation, and thereby delivers the strongest known “second signal” in the activation and survival of T cells by T cell receptor/CD3¹. Moreover, costimulation through CD28, stabilizing interleukin 2 (IL-2) gene transcription and translation, is critical for IL-2 production by T cells².

In healthy individuals, CD28 is constitutively expressed by almost all CD4⁺ and more than 50% of CD8⁺ T cells. The number of CD28⁻ T cells is extremely low in normal newborns³, and increases gradually with age⁴.

Many studies have demonstrated a defective expression of CD28 on T cells, as a consequence of the expansion of CD8⁺CD28⁻ and sometimes also of a small CD4⁺CD28⁻ population, in clinical conditions characterized by immune activation such as human immunodeficiency virus infection³⁻⁸,

organ transplant⁹, acute viral infections¹⁰, or autoimmune diseases such as systemic lupus erythematosus¹¹ and rheumatoid arthritis (RA)¹². In RA, the expansion of CD28⁻ T cells is associated with aggressive disease, extraarticular manifestations¹³, and preclinical atherosclerotic changes, including arterial endothelial dysfunction, suggesting that they may contribute to early atherosclerotic damage in these patients¹⁴.

It has been shown that downmodulation of CD28 cellular surface marker expression can be obtained with engagement with its ligand¹⁵, prolonged stimulation with specific peptide antigens¹⁶, or even with cytokines such as IL-4¹⁷ or IL-2¹⁸. The CD28⁻ T cell population displays some functional properties of differentiated effector cells^{18,19}. For a phenotypic identification of these populations, it is currently accepted that memory CD4⁺ and CD8⁺ T cells are generally CD45RA-negative and comprise at least 2 functionally distinct subsets: (1) nonpolarized “central memory” T cells (TCM), which express the chemokine receptor CCR7 and home to the T cell areas of secondary lymphoid organs; and (2) polarized “effector memory” T cells (TEM), which have lost the expression of CCR7 and have acquired the capacity to migrate to nonlymphoid tissues²⁰⁻²². Therefore, the evaluation of CCR7 together with CD45RA is now considered the best available way to enumerate TCM and TEM.

From the Rheumatology and Clinical Immunology Service, Spedali Civili and University of Brescia, Brescia, Italy.

M. Scarsi, MD; T. Ziglioli, MD; P. Airò, MD, Rheumatology and Clinical Immunology Service, Spedali Civili and University of Brescia.

Address correspondence to Dr. P. Airò, Rheumatology and Clinical Immunology Service, Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy. E-mail: airo@bresciareumatologia.it

Accepted for publication December 3, 2009.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2010. All rights reserved.

A third subset of memory T cells expresses CD45RA as do naive cells, but not CCR7. Various terms, these are highly differentiated cells, with persisting effector functions ("terminally differentiated effector memory", TTDEM)²³.

Abatacept is a fusion protein (CTLA4-Ig) that can act as a costimulation blocker binding to CD80 and CD86 on antigen-presenting cells, blocking the engagement of CD28 on T cells and preventing T cell activation, and it has proven useful in the treatment of patients with RA, including those refractory to tumor necrosis factor- α (TNF- α) blocking agents^{24,25}.

Our aim was to verify that blockade of CD28 costimulation by treatment with abatacept in patients with RA refractory to TNF- α inhibition might induce a reduction in the number of circulating CD28- T cells, as well as of other effector T cell populations, and to evaluate whether these variations are correlated with clinical response.

MATERIALS AND METHODS

Patients. Twenty consecutive patients with a diagnosis of RA, as defined by the 1987 American College of Rheumatology criteria²⁶, who had previously failed 1 or more TNF-blocking therapies, were treated with abatacept by intravenous infusion according to baseline weight (< 60 kg, 500 mg; 60–100 kg, 750 mg; and > 100 kg, 1000 mg) on days 1, 15, 29, and then monthly. The study was conducted in accord with the recommendations of the Helsinki Declaration, all investigations were those routinely required to evaluate the patients, and all patients gave informed consent for all procedures. Clinical assessment of patients was performed using the Disease Activity Score 28-joint count based on C-reactive protein (DAS28), and clinical response was evaluated with the European League Against Rheumatism (EULAR) response criteria²⁷. Main clinical and laboratory data of these patients are summarized in Table 1.

Twenty-seven healthy volunteers (median age 49 yrs) were recruited among laboratory personnel as controls.

Leukocyte phenotype analysis. Peripheral blood lymphocyte surface markers were evaluated by 4-color flow cytometry (Cytomics FC-500, Beckman

Coulter Inc., Fullerton, CA, USA) at the moment of the first infusion with abatacept (t = 0), and at weeks 4, 12, 24, and 48, using various combinations of monoclonal antibodies (CD3, CD4, CD8, CD45RA, CD45R0, CD28, CCR7; Beckman Coulter or R&D Systems Inc., Minneapolis, MN, USA), to identify naive, TCM, TEM, and TTDEM lymphocyte subpopulations. Absolute cell count was determined by single-platform analysis using Flow-Count beads (Beckman Coulter).

Statistical analysis. Data are expressed as the median (25th–75th percentile, interquartile range). The comparisons were made using the Mann-Whitney test. The variations of cell populations over time were evaluated by standard one-way analysis of variance. Correlations were evaluated by simple linear regression analysis.

RESULTS

Main demographic and clinical data of 20 patients with RA who previously failed TNF-blocking therapy are shown in Table 1. This was a cohort of patients particularly resistant to treatment as demonstrated by the high number of disease-modifying antirheumatic drugs used and because most of them previously received more than 1 TNF blocker, and in 6 cases also rituximab, without success.

One patient discontinued abatacept for elective surgery to treat an osteoporotic fracture after 1 month. Twelve of 19 evaluable patients (62%) achieved a clinical response according to the EULAR criteria (in 6 cases moderate and in 6 cases good response). Three patients discontinued abatacept at 3 months because of inefficacy and were not evaluated in the longitudinal immunophenotypic study. However, their baseline levels of CD28- T cells were not significantly different from other patients.

In this heavily pretreated cohort of 16 evaluable patients, the proportion of CD8+CD28- cells at baseline was higher than in healthy controls of comparable age [38.7% (24.9–62.3) vs 24.7% (15.4–28.7); p = 0.048]. Also, the proportion and the absolute number of CD4+CD28- T cells were higher in the patient group [4.8% (4.1–15.1) vs 3.6% (2.2–4.2); p = 0.029, and 49 cells/ μ l (32–75) vs 21 (14–35); p = 0.004, respectively].

The variations of T cell subsets after treatment with abatacept are shown in Table 2. The proportion of CD8+CD28- T cells progressively decreased with time (p = 0.008 comparing baseline and week 48; Figure 1). Despite a moderate rise of the absolute number of total CD8+ T cells, the absolute number of the CD8+CD28- population also significantly decreased from baseline to week 48 (p = 0.055). Accordingly, the proportion of the CD8+CD45RA+CCR7-, a phenotype thought to represent TTDEM cells, decreased (p = 0.03). Conversely, the proportions of CD8+CD28+ and that of TCM CD8+ cells increased (p = 0.002) from baseline to week 48. There was also a moderate, although not statistically significant, reduction of CD4+CD28- T cells.

Interestingly, variations of the T cell subpopulation after therapy with abatacept correlated with the clinical response [variation of the DAS28 (CRP); Figure 2]: in particular, direct correlations were found between DAS28 (CRP)

Table 1. Patient characteristics at baseline. Medians, except for HAQ score, are interquartile range (25th–75th percentile).

Characteristic	Patients (n = 20)
Age, median, yrs	55 (47–63)
Men	4
Women	16
Disease duration at inclusion, median	12.5 (9–20.75)
No. previous DMARD treatments, median	4 (2.75–5)
No. previous anti-TNF agents, median	2 (1.75–3)
Prior rituximab treatments	6
Concomitant DMARD treatments	
Methotrexate	18
Other DMARD	0
None	2
Rheumatoid factor positivity (%)	14 (70)
DAS28 (CRP) median	5.53 (5.05–6.35)
HAQ score median	1.25 (0.875–1.375)

DMARD: disease-modifying antirheumatic drugs; DAS28 (CRP): Disease Activity Score in 28 joints (C-reactive protein); HAQ: Health Assessment Questionnaire; TNF: tumor necrosis factor.

Table 2. Variations of percentages and absolute numbers of T cell subsets in patients with rheumatoid arthritis after treatment with abatacept. Numbers in 2nd line of each box are absolute numbers (cell/ μ l).

Lymphocyte Subtype	Baseline	48 Weeks	
CD3+CD4+ % of total lymphocyte	59.2 (46.9–70.3)	63.3 (51.1–70.4)	0.472
No. cells	749 (322–1773)	851 (328–1438)	0.937
CD3+CD4+ naïve % of total CD3+CD4+	37.2 (22.1–38.9)	33.1 (21.8–36.8)	0.556
No. cells	216 (135–445)	325 (148–446)	0.790
CD3+CD4+ CM % of total CD3+CD4+	41.1 (34.5–44.6)	54.1 (42.1–57.2)	0.061
No. cells	292 (200–411)	466 (316–702)	0.473
CD3+CD4+ EM % of total CD3+CD4+	20.3 (14.7–25.1)	14.7 (10.5–17.6)	0.519
No. cells	149 (113–227)	124 (87–153)	0.399
CD3+CD4+ TDEM % of total CD3+CD4+	1.25 (0.6–2.5)	0.8 (0.5–1.6)	0.270
No. cells	12 (5–22)	6 (4–12)	0.449
CD3+CD4+ EFF TOT % of total CD3+CD4+	21.5 (15.4–31.2)	16 (10.8–18.8)	0.352
No. cells	163 (129–261)	135 (93–159)	0.296
CD3+CD4+CD28+ % of total CD3+CD4+	95.2 (84.9–95.9)	96.9 (90.3–98.6)	0.349
No. cells	680 (446–879)	825 (510–1162)	0.954
CD3+CD4+CD28– % of total CD3+CD4+	4.8 (4.1–15.1)	3.0 (1.4–9.7)	0.349
No. cells	49 (32–75)	20 (15–27)	0.257
CD3+CD8+ % of total lymphocyte	20.4 (13.0–28.6)	21.4 (13.0–27.9)	0.941
No. cells	188 (128–581)	288 (79–502)	0.927
CD3+CD8+ naïve % of total CD3+CD8+	18.6 (12.6–31.8)	27.2 (20.6–35.0)	0.342
No. cells	48 (23–91)	88 (29–160)	0.304
CD3+CD8+ CM % of total CD3+CD8+	11.5 (7.1–13.7)	22.3 (15.6–32.5)	0.002
No. cells	29 (15–43)	44 (17–117)	0.128
CD3+CD8+ EM % of total CD3+CD8+	29.9 (23.2–42.2)	26.8 (20.9–33.7)	0.377
No. cells	81 (57–121)	64 (37–86)	0.276
CD3+CD8+ TDEM % of total CD3+CD8+	32.0 (20.4–41.3)	21.8 (9.7–25.7)	0.033
No. cells	72 (52–112)	26 (17–48)	0.132
CD3+CD8+ EFF TOT % of total CD3+CD8+	68.7 (54.5–78.6)	49.3 (31.4–58.8)	0.040
No. cells	170 (108–234)	85 (61–132)	0.138
CD3+CD8+CD28+ % of total CD3+CD8+	61.3 (37.7–75.1)	77.6 (74.0–87.6)	0.009
No. cells	124 (85–267)	249 (99–400)	0.528
CD3+CD8+CD28–	38.7 (24.9–62.3)	22.3 (12.1–25.9)	0.008
No. cells	109 (85–145)	32 (30–41)	0.055

decrease and the reductions of the percentages of circulating CD4+CD28– and CD8+CD28– T cells ($r = 0.58$, $p = 0.014$, and $r = 0.47$, $p = 0.059$, respectively), and total effector (CCR7–) CD8+ T cells ($r = 0.59$, $p = 0.012$).

DISCUSSION

Our main finding was the progressive reduction after treatment with abatacept of the number of circulating CD8+CD28– T cells, a population of differentiated effector lymphocytes that is characteristically raised in patients with RA. Since downmodulation of the costimulatory receptor CD28 follows its ligation by CD80/CD86¹⁵, it is conceivable that abatacept, a CTLA4-Ig construct preventing CD28 binding to CD80/CD86, also prevents generation of the CD28– population. The reduction of CD8+ cells with TTDEM phenotype can be easily explained by the fact that this subset largely overlaps with the CD8+CD28– population. The CD4+CD28– population was much smaller than the CD8+ counterpart at baseline, as described by others^{12–14}. A trend toward a reduction of this subset after abatacept therapy was also observed, but it did not reach statistical significance.

Importantly, however, the decreases of CD28– cells among both CD4+ and CD8+ T lymphocyte populations after abatacept therapy were correlated with clinical response as measured by the decrease of the DAS28 (CRP).

To our knowledge, there are no similar data in the literature. It is possible that other therapies in addition to abatacept can induce changes of CD28– T cell populations, particularly TNF-blocking agents. Indeed, downmodulation of CD28 on CD28+ T cells can be obtained *in vitro* by cultivating them in the presence of TNF- α ²⁸, and it has been shown in a small series of patients with RA that treatment with infliximab, a TNF-blocking agent, but not with methotrexate, may decrease the number of circulating CD4+CD28– lymphocytes²⁹, but this decrease was not correlated with clinical response. However, this study evaluated a limited number of patients ($n = 7$) and reported results concerning only the CD4+CD28– population.

Nevertheless, it is interesting that a study of synovial biopsies after abatacept therapy showed a particular reduction of interferon- γ (IFN- γ) expression that correlated well with improvements of a synovial magnetic resonance index³⁰. IFN- γ is mainly produced by effector CD8+ T cells,




Figure 1. Evolution of percentage and absolute number of CD8+CD28- T cells during therapy with abatacept.

and the large majority of this population has a CD28- phenotype. This observation is therefore in keeping with our results, and suggests that one of the mechanisms by which abatacept might obtain its clinical effect is modulation of effector (CD28-) T cell function.

Because studies on chemokine receptor expression on CD4+CD28- T cells in patients with RA showed that these cells have an unusual tissue-trafficking pattern and, despite being end-differentiated effector cells, may be able to survive in lymphoid tissues³¹, it may be suggested that these cells have a role in manifestations elsewhere than in the joints. Future studies are therefore warranted to evaluate the effect of abatacept in secondary lymphoid organs. Moreover, the influence of this therapy on cardiovascular events in patients with RA should be addressed, because a strict correlation of CD4+CD28- lymphocytes with subclinical atherosclerosis has been observed in these patients^{14,32}. Indeed, the observation that these effector T cells are expanded in patients with unstable angina, where they may invade the atherosclerotic plaque, suggested their direct involvement in plaque disruption³³, where they may produce IFN- γ capable of destabilizing the atherosclerotic plaque^{14,33}.

The main limitations of our study, besides the lack of functional data and of tissue analysis, are the small number of patients evaluated and the relatively short period of observation (1 year). However, the observation of a

decreased number of circulating CD28- T cells after treatment with abatacept in patients with RA and correlation with clinical response may draw attention to this area and to further research. Research should aim at confirming our observations, and to extending them with longer followup, considering the high longterm safety and efficacy profile of abatacept³⁴.

ACKNOWLEDGMENT

We thank Dr. Fabio Malacarne for advice and suggestions. The skillful technical assistance of Dora Rossi and Carla Bosio is gratefully acknowledged.

REFERENCES

1. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. *Annu Rev Immunol* 1993;11:191-212.
2. Crispin J, Tsokos GC. Transcriptional regulation of IL-2 in health and autoimmunity. *Autoimmun Rev* 2009;8:190-5.
3. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. *J Immunol* 1993;150:1147-59.
4. Hoshino T, Yamada A, Honda J, Imai Y, Nakao M, Inoue M, et al. Tissue-specific distribution and age-dependent increase of human CD11b+ T cells. *J Immunol* 1993;151:2237-46.
5. Saukkonen JJ, Kornfeld H, Berman JS. Expansion of a CD8+CD28- cell population in the blood and lung of HIV-positive patients. *J Acquir Immune Defic Syndr* 1993;6:1194-204.
6. Choremi-Papadoupoulou H, Viglis V, Gargalianos P, Kordossis Y, Iniotaki-Theodoraki A, Kosmidis J. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV infection. *J Acquir Immune Defic Syndr* 1994;7:245-53.




Figure 2. Correlations of variations of T cell subpopulation percentages with variation of the Disease Activity Score (DAS28) during therapy with abatacept.

7. Brugnoli D, Prati E, Malacarne F, Gorla R, Airò P, Cattaneo R. The primary response to HIV infection is characterized by an expansion of activated CD8+ CD28- cells. *AIDS* 1996;10:104-6.
8. Brugnoli D, Airò P, Timpano S, Malacarne F, Ugazio AG, Cattaneo R, et al. CD8+CD28- T cells in vertically HIV-infected children. *Clin Exp Immunol* 1997;109:412-5.
9. Kern F, Ode-Hakim S, Vogt K, Hoeflich C, Reinke P, Volk HD. The enigma of CD57+CD28- T cell expansion — anergy or activation? *Clin Exp Immunol* 1996;104:180-4.
10. Borthwick NJ, Bofill M, Hassan I, Panayiotidis P, Janosy G, Salmon M, et al. Factors that influence activated CD8+ T cell apoptosis in patients with acute herpesvirus infections: loss of costimulatory molecules CD28, CD5 and CD6 but relative maintenance of Bax and Bcl-x expression. *Immunology* 1996;88:508-15.
11. Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. *Clin Exp Immunol* 1996;106:18-29.
12. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. *J Clin Invest* 1996;97:2027-37.
13. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. *Arthritis Rheum* 1997;40:1106-14.
14. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. *Circulation* 2004;109:2744-8.
15. Linsley PS, Bradshaw J, Urnes M, Grosmaire L, Ledbetter J. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. *J Immunol* 1993;150:3161-9.
16. Lake RA, O'Hehir RE, Verhoef A, Lamb JR. CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide. *Int Immunol* 1993;5:461-6.
17. Lloyd TE, Yang L, Tang DN, Bennett T, Schober W, Lewis DE. Regulation of CD28 costimulation in human CD81 T cells. *J Immunol* 1997;158:1551-8.
18. Fiorentini S, Malacarne F, Ricotta D, Licenziati S, Solis AA, Ausenda S, et al. Generation of CD28- cells from long-term-stimulated CD8+CD28+ T cells: a possible mechanism

- accounting for the increased number of CD8+CD28+ T cells in HIV-1-infected patients. *J Leukoc Biol* 1999;65:641-8.
19. Vingerhoets JH, Vanham GL, Kestens LL, Penne GG, Colebunders RL, Vandenbruaene MJ, et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 downregulation on CD8+ T cells. *Clin Exp Immunol* 1995;100:425-33.
 20. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 1999;401:708-12.
 21. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4+ T Cells. *J Exp Med* 2001;194:1711-9.
 22. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. *Blood* 2003;101:4260-6.
 23. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: Central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. *Mech Ageing Dev* 2006;27:274-81.
 24. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N Engl J Med* 2003;349:1907-15.
 25. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med* 2005;353:1114-23.
 26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
 27. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis* 2009;68:954-60.
 28. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor a therapy in rheumatoid arthritis. *Arthritis Rheum* 2005;52:2996-3003.
 29. Gerli R, Bartoloni-Bocci E, Shoenfeld Y. Effect of tumor necrosis factor a inhibition on CD28 surface expression on CD4+ T cells. *Arthritis Rheum* 2006;54:3060-1.
 30. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. *Ann Rheum Dis* 2009;68:1220-7.
 31. Zhang X, Nakajima T, Goronzy JJ, Weyand CM. Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis. *Arthritis Rheum* 2005;52:3839-49.
 32. Gerli R, Vaudo G, Bartoloni-Bocci E, Schillaci G, Bistoni O, Shoenfeld Y. Different roles for anti-cyclic citrullinated peptide antibodies and CD4+CD28null cells in the acceleration of atherosclerosis in rheumatoid arthritis. *Arthritis Rheum* 2009;60:631-2.
 33. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. *Circulation* 2000;101:2883-8.
 34. Westhovens R, Kremer JM, Moreland L, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. *J Rheumatol* 2009;36:736-42.